Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis

Gastroenterology. 1999 Sep;117(3):645-52. doi: 10.1016/s0016-5085(99)70458-0.

Abstract

Background & aims: Polymorphisms that control cytokine production can affect immunoregulation. The frequency and consequences of these polymorphisms in type 1 autoimmune hepatitis were determined.

Methods: DNA samples from 155 patients and 102 ethnically similar normal individuals were assessed by polymerase chain reaction for polymorphisms of 4 different cytokine-producing genes.

Results: Only genotypes associated with the guanine to adenine substitution at position -308 of the tumor necrosis factor gene occurred more commonly in patients than in normal subjects (56% vs. 26%; P < 0.001). Patients with this polymorphism had the HLA DRB1*0301 allele (81% vs. 10%; P < 0.000001) and A1-B8-DRB1*0301 (66% vs. 0%; P < 0.000001) phenotype more frequently and HLA DRB1*04 alleles less often (24% vs. 67%; P < 0.000001). They also entered remission less commonly (56% vs. 78%; P = 0.01), had treatment failure more often (20% vs. 7%; P = 0.03), and developed cirrhosis more frequently (40% vs. 19%; P = 0.05). These latter differences, however, were not statistically significant by adjusted P value.

Conclusions: A polymorphism of the tumor necrosis factor gene occurs more commonly in patients with type 1 autoimmune hepatitis than in normal subjects; it is associated with a poorer response to corticosteroids. The polymorphism may be inherited as part of the extended A1-B8-DRB1*0301 haplotype and may affect both disease expression and behavior.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Autoantibodies / analysis
  • Cytokines / biosynthesis
  • Cytokines / genetics*
  • DNA / analysis
  • Female
  • Genotype
  • Glucocorticoids / therapeutic use
  • HLA-D Antigens / genetics
  • Hepatitis, Autoimmune / drug therapy
  • Hepatitis, Autoimmune / genetics
  • Hepatitis, Autoimmune / immunology*
  • Hepatitis, Autoimmune / physiopathology
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Male
  • Middle Aged
  • Polymerase Chain Reaction
  • Polymorphism, Genetic
  • Prednisone / therapeutic use
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / genetics

Substances

  • Autoantibodies
  • Cytokines
  • Glucocorticoids
  • HLA-D Antigens
  • Immunosuppressive Agents
  • Tumor Necrosis Factor-alpha
  • DNA
  • Prednisone